BioPharmX (BPMX) Sees Strong Trading Volume After Insider Buying Activity
BioPharmX (NASDAQ:BPMX) saw an uptick in trading volume on Wednesday following insider buying activity. 1,356,384 shares traded hands during trading, an increase of 445% from the previous session’s volume of 249,006 shares.The stock last traded at $0.31 and had previously closed at $0.28.
Specifically, Director Stephen Morlock purchased 428,571 shares of BioPharmX stock in a transaction dated Monday, November 28th. The shares were bought at an average cost of $0.35 per share, with a total value of $149,999.85. Following the completion of the transaction, the director now directly owns 543,956 shares in the company, valued at approximately $190,384.60. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Separately, HC Wainwright restated a “buy” rating on shares of BioPharmX in a report on Saturday, September 17th.
The company has a 50 day moving average price of $0.29 and a 200 day moving average price of $0.57. The company’s market cap is $9.66 million.
BioPharmX Company Profile
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for BioPharmX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioPharmX and related companies with MarketBeat.com's FREE daily email newsletter.